Clinical trialNCT04476329TerminatedPhase 2Interventional

Optimization for Regorafenib in HCC

SponsorSC Liver Research Consortium, LLCEnrollment7Hepatocellular Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized, two arm, phase II study of 1st Cycle dose optimization for regorafenib treatment compared to standard dose of regorafenib treatment in HCC patients for whom the physician is intending to treat with regorafenib and who failed any 1st line systemic treatment.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Catherine T Frenette, MD
Scripps MD Anderson Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Madappa Kundranda, MD
Banner MD Andersen Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
Va Long Beach Health System
Long Beach, California, United States
Tulane University
New Orleans, Louisiana, United States
Henry Ford Health Systems
Detroit, Michigan, United States
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan, United States
Saint Louis University
St Louis, Missouri, United States
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Regorafenib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Jan 2021
Primary completion: 13 Oct 2021
Completion: 10 Dec 2021
Last update posted: 30 Dec 2021
Registered enrollment: 7
Registry id: NCT04476329

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.